CompletedNCT01039454
How GSK598809 affects brain responses to food reward
About this title
Read the official source — NCT01039454Medication studyAges 18–45United KingdomAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- Cambridge and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: December 18, 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT01039454
- Official title
Show the full official title
A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge · London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including GSK598809 Capsules and GSK598809 Placebo Capsules.
Who was this study for?
Listed age limits: 18 years to 45 years.
